STOCK TITAN

Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Meridian Bioscience, a leader in diagnostic testing, has launched two new master mixes: Lyo-Ready™ Direct DNA qPCR Saliva Mix and Lyo-Ready™ Direct RNA/DNA qPCR Saliva Mix. These mixes enhance the detection of DNA and RNA in crude saliva samples, improving assay sensitivity and simplifying protocols. Designed for use in both liquid and lyophilized formats, they address challenges posed by PCR inhibitors in saliva. This launch comes at a critical time with rising respiratory infections, making saliva testing more urgent. Meridian aims to lead in innovative diagnostic solutions.

Positive
  • Launch of two new master mixes enhancing DNA/RNA detection in saliva.
  • Improved assay sensitivity and ease of use for diagnostic testing.
  • Product stability in liquid or lyophilized formats supports diverse applications.
Negative
  • None.

CINCINNATI, Jan. 28, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude saliva samples.  These two new mixes, Lyo-Ready™ Direct DNA qPCR Saliva Mix and Lyo-Ready™ Direct RNA/DNA qPCR Saliva Mix can be used in liquid format or lyophilized.  Both mixes accelerate the development of diagnostic assays and improve assay sensitivity using saliva samples with direct qPCR protocols.

Saliva is a non-invasive clinical sample utilized for diagnostic testing across many diseases, including cancer, HIV, and respiratory diseases (e.g., flu, bronchiolitis, pneumonia, and COVID-19).  Saliva is one of the easiest samples to collect and handle; however, PCR inhibitors naturally present in high concentrations in the sample create challenges in developing highly sensitive and reliable saliva-based assays. 

Similar to the innovative portfolio of Air-Dryable™ sample-specific master mixes, Meridian's new Lyo-Ready™ saliva-specific master mixes are optimized for use on crudely processed saliva or sputum samples for enhanced assay sensitivity and flexible protocols.  They are "ready-to-use," with no further optimization required aside from the addition of primers and probes.  Additionally, these mixes are stable in a liquid format or can be lyophilized to create ambient temperature-stable assays for point-of-care applications.

Lourdes Weltzien, Ph.D., Executive Vice President - Life Science, commented, "With the surge of COVID-19 infections caused by the Omicron variant along with a rapid increase of other respiratory infections, the need for direct saliva testing has never been greater.  Direct RT-qPCR saliva assays offer fast and convenient sample analysis, improve logistics and reduce costs involved in sample handling and transport.  We are pleased to be the first to offer a complete solution for anyone developing a saliva-based molecular assay, whether in liquid, lyophilized or air-dried format."

Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. To learn more about Meridian's innovative mixes, visit https://www.meridianbioscience.com/lifescience/products/molecular-reagents/ambient-temperature-rt-qpcr-qpcr-mixes or email Florent.Chang-Pi-Hin@meridianlifescience.com.

About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing.  We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone:  +1 513.271.3700
Email: mbi@meridianbioscience.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/meridian-bioscience-launches-lyo-ready-qpcr-saliva-specific-master-mixes-for-dna--rna-direct-detection-301470634.html

SOURCE Meridian Bioscience, Inc.

FAQ

What new products has Meridian Bioscience launched?

Meridian Bioscience launched Lyo-Ready™ Direct DNA qPCR Saliva Mix and Lyo-Ready™ Direct RNA/DNA qPCR Saliva Mix.

How do Lyo-Ready™ mixes improve saliva testing?

These mixes enhance assay sensitivity and simplify the testing process for DNA and RNA detection.

What is the significance of saliva testing in diagnostics?

Saliva testing is non-invasive and crucial for diagnosing various diseases, including respiratory infections.

When was the press release about the new master mixes issued?

The press release was issued on January 28, 2022.

What is the stock symbol for Meridian Bioscience?

The stock symbol for Meridian Bioscience is VIVO.

VIVO

NASDAQ:VIVO

VIVO Rankings

VIVO Latest News

VIVO Stock Data

1.49B
43.35M
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Cincinnati